华海药业：预计2024年1-3月归属净利润盈利2.6亿元至2.85亿元

证券之星04-15

证券之星消息，华海药业发布业绩预告，预计2024年1-3月归属净利润盈利2.6亿元至2.85亿元。公告中解释本次业绩变动的原因为：报告期内，公司实现归属于上市公司股东的净利润及归属于上市公司股东的扣除非经常性损益的净利润较去年同期均大幅增长，主要是：（1）新产品持续导入并逐步上量，市场拓展初显成效；（2）深化销售团队裂变及组织架构调整，市场管理触角不断向下延伸牵引销售团队持续深挖市场、推进全球销售...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2427078765?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-15 18:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2427078765","market":"sh","top_or_hot":-1,"title":"华海药业：预计2024年1-3月归属净利润盈利2.6亿元至2.85亿元","media":"证券之星","content":"<div>\n<p>证券之星消息，华海药业发布业绩预告，预计2024年1-3月归属净利润盈利2.6亿元至2.85亿元。公告中解释本次业绩变动的原因为：报告期内，公司实现归属于上市公司股东的净利润及归属于上市公司股东的扣除非经常性损益的净利润较去年同期均大幅增长，主要是：（1）新产品持续导入并逐步上量，市场拓展初显成效；（2）深化销售团队裂变及组织架构调整，市场管理触角不断向下延伸牵引销售团队持续深挖市场、推进全球销售...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415180136877f012d&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>华海药业：预计2024年1-3月归属净利润盈利2.6亿元至2.85亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n华海药业：预计2024年1-3月归属净利润盈利2.6亿元至2.85亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-15 18:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415180136877f012d&s=b><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，华海药业发布业绩预告，预计2024年1-3月归属净利润盈利2.6亿元至2.85亿元。公告中解释本次业绩变动的原因为：报告期内，公司实现归属于上市公司股东的净利润及归属于上市公司股东的扣除非经常性损益的净利润较去年同期均大幅增长，主要是：（1）新产品持续导入并逐步上量，市场拓展初显成效；（2）深化销售团队裂变及组织架构调整，市场管理触角不断向下延伸牵引销售团队持续深挖市场、推进全球销售...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415180136877f012d&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600521","symbol_name":"华海药业","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415180136877f012d&s=b","article_id":"2427078765","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415180136877f012d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2427078765","pubTimestamp":1713175233,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"证券之星消息，华海药业发布业绩预告，预计2024年1-3月归属净利润盈利2.6亿元至2.85亿元。华海药业2023年三季报显示，公司主营收入62.08亿元，同比上升6.33%；归母净利润7.22亿元，同比下降9.18%；扣非净利润7.69亿元，同比下降8.29%；其中2023年第三季度，公司单季度主营收入19.13亿元，同比下降5.02%；单季度归母净利润1.53亿元，同比下降32.57%；单季度扣非净利润1.47亿元，同比下降42.34%；负债率55.21%，投资收益-5480.12万元，财务费用6749.99万元，毛利率58.96%。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"600521":"华海药业"},"translate_title":"Huahai Pharmaceutical: It is estimated that the attributable net profit from January to March 2024 will be 260 million to 285 million yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600521":0.9},"content_text":"证券之星消息，华海药业发布业绩预告，预计2024年1-3月归属净利润盈利2.6亿元至2.85亿元。公告中解释本次业绩变动的原因为：报告期内，公司实现归属于上市公司股东的净利润及归属于上市公司股东的扣除非经常性损益的净利润较去年同期均大幅增长，主要是：（1）新产品持续导入并逐步上量，市场拓展初显成效；（2）深化销售团队裂变及组织架构调整，市场管理触角不断向下延伸牵引销售团队持续深挖市场、推进全球销售网络布局、积极开拓新兴市场、提升差异化服务水平，客户粘性不断增强，产品市场占有率有效提升，销售收入大幅增长；（3）精益管理持续优化，技改能力不断提升叠加规模效应，公司成本控制能力及综合实力进一步增强。华海药业2023年三季报显示，公司主营收入62.08亿元，同比上升6.33%；归母净利润7.22亿元，同比下降9.18%；扣非净利润7.69亿元，同比下降8.29%；其中2023年第三季度，公司单季度主营收入19.13亿元，同比下降5.02%；单季度归母净利润1.53亿元，同比下降32.57%；单季度扣非净利润1.47亿元，同比下降42.34%；负债率55.21%，投资收益-5480.12万元，财务费用6749.99万元，毛利率58.96%。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2427078765"}